

QIBA Diffusion-Weighted Imaging MR Biomarker Committee (BC) Meeting

Tuesday, February 28, 2023, at 1 pm (CT)

Meeting Summary

Participants

Michael Boss, PhD (Co-chair)

Dariya Malyarenko, PhD (Co-chair)

Daniel Margolis, MD (Co-chair)

Trevor Andrews, PhD

Rajpaul Attariwala, MD, PhD

Ishtiaq Bercha, MSc, MSEE

Thomas Chenevert, PhD

Amita Shukla Dave, PhD

Nandita deSouza, MD

Moti Freiman, PhD

Kevin Miller, MS

Peter Ngum, MSc

Nancy Obuchowski, PhD

Savannah Partridge, PhD

Dafna Sourani-Link, PhD

Lisa Wilmes, PhD

Jessica M. Winfield, PhD

RSNA

Susan Stanfa

Topics:

- MR CC updates: venues for Profile adoption by clinical community (research symposia, clinical trial CROs)
- DWI Profile Stage 3 approval: reformatting, new assessment procedures and white paper
- UCL (VERDICT) ADC repeatability prospective study to inform improvement of precision of prostate measurements
- Whole Body DWI Profile Proposal

Next Steps / Action Items:

Stage 3 DWI Profile

Previous DWI-MR BC MOTION APPROVED to publish the DWI BC Stage 3 Profile:

- The motion passed unanimously via eBallot with 7 votes in favor, 0 against, 0 abstentions, and 0 recusals

Previous MR CC MOTION APPROVED to publish the DWI BC Stage 3 Profile:

- The motion passed unanimously via eBallot with 14 votes in favor, 0 against, 0 abstentions, and 0 recusals

- Appendix B Acknowledgements section was updated to include all contributors
- Future Profile directions include transitioning to streamlined Profile template, adding cross-sectional Claims, kurtosis imaging, and incorporation of new QA procedures, e.g., thermometry
- Addition of Assessment Procedures for easier implementation and white paper efforts to be done in parallel
- Stage 3 Profile to have potential immediate impact on new trial concepts involving the apparent diffusion coefficient; hope for incorporation into clinical trials overseen by NCTN groups
- Discussion of ways to promote Profile application in clinical world
 - Organize QIBA-related symposia during MR-related research meetings, e.g., ISMRM
 - Contact CROs / iCROs involved in deciding on protocols used in clinical trials
 - Reach out to European trials groups, e.g., European Organization of Research and Treatment in Cancer (EORTC), which runs a substantial portion of European trials in cancer and could send the DWI Profile protocol to disease-oriented groups for review
 - Leverage QIBA pharma and iCRO contacts for invitation-only interactive webinars to include QIBA education on importance of standardization
- QIBA Leadership and RSNA staff to be contacted to discuss exploring the development of a series of general QIBA webinars, as well as a CRO-focused DWI-specific one; development of these outreach efforts can benefit from previous work, e.g., MRE Stage 3 Profile, etc.
- [QIBA YouTube videos were referenced](#)
- CaliberMRI is creating a reference library on their website and offered to host recorded DWI Profile webinar content
- Transition to streamlined Profile template to be completed prior to webinar development
- Dr. Zahlmann to be contacted regarding possible DWI Profile implementation at Australian sites

- Clinical trial networks, CROs, iCROs, pharma company, etc. outreach efforts (with contacts) to be tracked in a Google Sheet
- White Paper progress to continue in parallel with Profile efforts

Next Steps:

- Whole Body DWI BC group to complete [New Biomarker Cmte Application Form](#)
- Dr. Dave to confirm white paper assignments
- Dr. Boss to be contacted if access to [white paper Google Doc](#) is needed (Gmail address recommended)
- Dr. Dave to invite Dr. Banerjee to present on AI tools for DWI during the Mar. 28 call; GE AI DWI testing ideas to be discussed
- H&N ADC repeatability groundwork project update to be provided during the Mar. 28 call

Next DWI-MR BC Meeting: Tuesday, March 28, 2023, at 1 p.m. (CT)

Participants are welcome to contact RSNA staff at giba@rsna.org if their attendance is not reflected in meeting summaries.